Chief Financial Officer
Sientra sold to TIger Aesthetics Medical, LLCPublicly traded, global Medical Device company (NASDAQ: SIEN) with $90M sales, 300 employees. Vertically integrated business (Manufacturing to Direct Sales Team) focused on the Aesthetics market including both the Cosmetic and Hospital-Reconstruction markets. In 2 years, transformed Company from a previous 10 year ‘Sales at all costs’ strategy to a ‘Pathway to profitability’ driven Company. Organizational Change Management focus and execution.• In 2021, part of Executive team guiding Company’s rebound from COVID shut downs managing 40%+ revenue growth.• In 2022, recapitalized Balance Sheet to provide ‘operational runway’. Reduced existing debt from $83M to $73M, moved debt maturities from 2023 to 2026-2027 with no increase in interest rate. Executed targeted equity raise.• In 2023, guided Company to first ever free-cash-flow positive performance (Q4 2023) in the Company’s 20+ year history.• In 2024, key team member associated with the successful sale of the Company for $122M in total consideration.